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What's new? • This is the first study to examine prospectively the associations between levels of and 
change in oestradiol and follicle-stimulating hormone (FSH) during the menopausal 
transition and incident diabetes in a cohort of women. • The study shows that, independent of age and other important risk factors of diabetes, 
women with lower pre-menopausal oestradiol levels and a slower rate of FSH change 
during the early menopause transition had a higher risk of developing diabetes. • Given that obesity plays an important role in diabetes risk as well as in the levels and 
changes in oestradiol and FSH over the menopausal transition, weight control in earlier 
mid-life is important to prevent future diabetes development. 
 
Abstract  
Aim  To investigate the association between changes in oestradiol and follicle-stimulating 
hormone levels during the menopausal transition and incident diabetes. 
Methods We followed 1407 pre-menopausal women, aged 42–52 years at baseline, who 
experienced natural menopause, from baseline to the 12th annual follow-up visit in the Study of 
Women’s Health Across the Nation (SWAN). Diabetes was defined based on fasting glucose 
level, medication use and self-report of physician diagnosis. Cox proportional hazards regression 
was used to evaluate the associations of incident diabetes with three components of the rate of 
change in hormones: the intercept (pre-menopausal levels) and two piece-wise slopes 
representing change during the early and late transition, respectively.  
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Results During 15 years of follow-up, 132 women developed diabetes. After adjusting for 
potential confounders, a higher oestradiol intercept, but not its rate of change, was borderline 
significantly associated with lower risk of diabetes [hazard ratio for an interquartile range 
increase (75.2 pmol/L) 0.53, 95% CI 0.27–1.06]. For follicle-stimulating hormone, a greater rate 
of increase in the early transition, but not the intercept or late transition, was significantly 
associated with lower risk of diabetes [hazard ratio for an interquartile range increase (5.9 
IU/L/year) 0.31, 95% CI 0.10–0.94].  
Conclusions Lower pre-menopausal oestradiol levels and a slower rate of follicle-stimulating 
hormone change during the early transition were associated with higher risk of developing 
diabetes. Given that obesity plays an important role in diabetes risk and in the levels and changes 
in oestradiol and follicle-stimulating hormone over the menopausal transition, weight control in 
earlier mid-life is important to prevent future diabetes development. 
 
Introduction 
Endogenous oestrogens may reduce the risk of developing diabetes in pre-menopausal 
women by lowering body fat and promoting insulin sensitivity [1]. Studies of oral contraceptives 
and menopausal hormone therapy support the notion that oestrogens play a preventive role in 
diabetes risk [2–4].  As women transition through the menopause, oestradiol levels drop 
considerably. Some cross-sectional studies have shown that oestradiol levels are higher in post-
menopausal women with diabetes [5–7], but others report no association [8,9].  Only a few 
prospective studies have examined the association between oestradiol and incident diabetes. Two 
studies in post-menopausal women (the Women’s Health Study [10] and the Multi-Ethnic Study 
of Atherosclerosis [11]) reported a significant association between higher levels of oestradiol and 
higher risk of diabetes, whereas the Rancho Bernardo Study found a non-significant positive 
association between oestradiol (both total and bioavailable levels) and incident diabetes in older 
women (aged 55–89 years) [12]; however, a recent report from the Diabetes Prevention Program 
failed to find an association between oestradiol and incident diabetes in either pre- or post-
menopausal women [13].  
 Prospective studies to date have been limited by assessing only hormone levels measured 
at baseline. Women’s hormone levels, especially oestradiol and follicle-stimulating hormone 
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(FSH), change dramatically during the menopausal transition. Oestradiol levels remain stable 
until ~ 2 years before the final menstrual period, then decline rapidly until ~2 years after the final 
menstrual period, and then stabilize once again; FSH gradually increases beginning ~7 years 
before the final menstrual period and then accelerates from 2 years before the final menstrual 
period until 1 year after the final menstrual period [14]. To date, however, no study has 
examined how change in sex steroid hormone levels during the menopausal transition influences 
diabetes risk in mid-life. The Study of Women’s Health Across the Nation (SWAN), a multi-site, 
multi-ethnic longitudinal study of the natural history of the menopausal transition includes 
annual or biannual hormone measurements over a 15-year period, as well as longitinal follow-up 
for incident diabetes. These data allow us to address the aforementioned limitation.  
In the present study, we investigated the association between change in serum sex steroid 
hormone levels during the menopausal transition including the late transition, the stage during 
which the most dramatic changes in the endogenous endocrine environment occur, and incident 
diabetes. We focused on oestradiol and FSH because our previous studies in SWAN have shown 
that testosterone, dehydroepiandrosterone and sex hormone-binding globulin are relatively stable 
over the menopausal transition stages [15,16].  
 
Methods 
Study population 
In the present analysis we used data from SWAN, details of which have been reported elsewhere 
[17]. Between 1996 and 1997, 3302 women were enrolled into the longitudinal cohort at seven 
study sites (Boston, MA; Chicago, IL; Detroit, MI; Los Angeles, CA; Newark, NJ; Oakland, CA; 
and Pittsburgh, PA). Each site recruited representative samples of at least 450 women: white 
women and women from one specified minority group (black in Boston, Chicago, Detroit, and 
Pittsburgh; Chinese in Oakland; Japanese in Los Angeles; Hispanic in Newark). Eligibility 
criteria included: age 42–52 years; having an intact uterus; having at least one menstrual period 
and not taking hormone medications (e.g. birth control pills, oestrogen or progesterone 
preparations) in the 3 months before the baseline survey; and having self-identified with the 
site’s designated race/ethnic groups. Institutional review board approval was obtained at each 
study site, and all participants provided signed informed consent at each study visit.  
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Menopausal status and date of the final menstrual period were determined from questions 
about menstrual bleeding on the annual visit questionnaires. Women who reported bleeding in 
the 3 months before an annual visit with no decrease in the predictability of menses in the year 
before the visit were categorized as pre-menopausal. Women who reported no menses for ≥12 
months were classified as post-menopausal. The final menstrual period was defined as the first 
day of the bleeding period which was followed by at least 12 months of amenorrhoea [18,19].  
Among the 3302 participants in SWAN, 1555 had an observed natural final menstrual 
period not masked by hormone use between the enrolment visit and the 12th
 
 follow-up visit 
(2009–2010) and thus were potentially eligible for this analysis. We excluded women who were 
ascertained to have diabetes at baseline (n=87); developed diabetes in the early peri-menopause 
(n=23) before marked changes in hormone levels; were pregnant during the follow-up (n=2); or 
were missing information on oestradiol and FSH (n=1). We further excluded the 35 women who 
were found to be in late peri-menopause (defined as a self-report of  >3 but <12 months of 
amenorrhoea) at baseline. Thus, the final eligible analytical sample included 1407 women.  
Outcome ascertainment 
Serum glucose levels were measured at all clinic visits except visits 9 and 10 using a hexokinase-
coupled reaction (Boehringer Mannheim Diagnostics, Indianapolis, IN, USA). Diabetes was 
ascertained at each visit if a participant met at least one of the following: (1) a fasting serum 
glucose level ≥7 mmol/L;  (2) current use of insulin or oral hypoglycaemic medication; and (3) 
self-report of physician diagnosis of diabetes. Almost all of the diabetes cases in this life stage can 
be assumed to be Type 2 diabetes.  
 
Sex hormone assessment 
In SWAN, oestradiol and FSH were assayed from serum samples obtained at each follow-up 
visit. The oestradiol assay was conducted in duplicate using the automated Ciba Corning 
Diagnostics ACS:180 analyzer (Bayer Diagnostics Corp., Norwood, MA, USA). The average 
inter- and intra-assay coefficients of oestradiol variation were 10.6% and 6.4%, respectively, 
over the oestradiol assay range, and the lower limit of detection was 3.67 pmol/L. A single FSH 
assay was conducted using a two-site chemiluminometric immunoassay. Inter- and intra-assay 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
coefficients of FSH variation were 12.0% and 6.0%, respectively, and the lower limit of 
detection was 1.1 IU/L.  
 
Other covariates 
Sociodemographic factors including age, race/ethnicity and educational attainment (less than 
high school, high school, some college, college or postgraduate) were obtained at the SWAN 
baseline examination. Self-reported smoking status (never, former, current) was collected at each 
examination. Height and weight were measured in women without shoes and in light clothing 
using a stadiometer and calibrated scale. BMI was calculated as weight in kilograms divided by 
height in meters squared. Obesity was defined as BMI ≥ 30 kg/m2
 
.  
Statistical methods 
Variable distributions were examined for normality, the presence of non-plausible outliers and 
changing variability over time. A two-stage approach was used to evaluate the associations of 
changes in hormones (oestradiol and FSH) with incident diabetes. In stage 1, among the 1407 
women in the analytical sample, all of whom had an observable natural final menstrual period, 
13 122 hormone observations were collected over the 12-year follow-up period (mean of 9.3 
observations/woman) for data analyses. To describe the trajectories of mean serum hormone 
levels over time in relation to the time before and after the final menstrual period, a multiple-step 
process was used to organize these data into trajectories of mean hormone levels and rates of 
change profiles in relation to the final menstrual period [20,21].  Piece-wise linear mixed effect 
modelling was used to estimate segmented rate of changes in hormones for three time periods 
based on previous modelling of the hormone trajectories [20,21], > 2 years before the final 
menstrual period,  from 2 years before to 2 years after the final menstrual period, and > 2 years 
after the final menstrual period. The rate of changes in hormones corresponding to the first two 
time periods characterizes the hormonal changes occurring in pre-/early transition stage, and the 
late transition to early post-menopausal stage. Thus we captured the effect of longitudinal change 
in hormone levels using trajectory models for each hormone that constituted their intercept and 
two piece-wise slopes. These subject-specific annualized slopes were used as independent 
variables in the next stage of analysis.  
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In stage 2, Cox proportional hazards regression analysis was used to model the 
association of the rate of change in hormone levels with the development of diabetes. Person-
years were computed from baseline to the date of the visit at which incident diabetes was 
ascertained, loss to follow-up or the date of the 12th
We also evaluated whether the effect of hormones on diabetes risk differed according to 
baseline obesity status by including interaction terms between each component of the rate of 
change and obesity. As the analytical design evaluated the effect of rate of change in sex 
hormone levels beginning from the baseline examination, we were able to evaluate effect 
modification by baseline obesity status but not by weight gain during the menopausal transition. 
Analyses were implemented in SAS version 9.3 (SAS Institute, Cary, NC, USA). A two-sided P 
value <0.05 was taken to indicate statistical signficance. 
 visit, whichever came first. Each hormone 
variable has three components: the intercept, which indicates baseline levels, and two piece-wise 
coefficients for time, which represent the rate of change during the early and late transitions, 
respectively. These three components were fit as continuous variables into the survival models. 
Hazard ratios and 95% CIs for the incident diabetes were calculated.  Potential confounding 
factors considered include baseline age, baseline BMI,  baseline smoking status, race/ethnicity, 
education and study site. Model goodness of fits were assessed using Akaike information criteria 
(AIC). In the final model, study site was not included because it is collinear with race/ethnicity 
and the results with and without study site remain unchanged. 
 
Results 
The mean (SD) age of the participants at baseline was 46.4 (2.7) years (Table 1). On 
average, women experienced the final menstrual period at 51.8 (2.7) years of age. During a 
median of 11 years of follow-up, 132 of 1407 women developed diabetes in late peri-menopause 
or post-menopause (9.4%; incidence of  9 per 1000 person-years). Baseline age and age at final 
menstrual period were not different between women who did and did not develop diabetes; 
however, women who developed diabetes during follow-up had lower baseline oestradiol levels 
than those who did not (median oestradiol 160.4 vs 213.6 pmol/L; median FSH 16.2 vs. 16.5 
IU/L). Women with incident diabetes were also more likely to be black or Hispanic, early peri-
menopausal, obese and current smokers at baseline than those without incident diabetes.  
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In age-adjusted models (Table 2, Model 1), the estimated oestradiol intercept (i.e. 
baseline – pre-menopausal – oestradiol) was significantly and inversely associated with incident 
diabetes, but the rate of change in oestradiol levels during the early and late menopausal 
transition were not associated with the risk of diabetes. Adjustment for BMI attenuated the 
associations (Table 2, Model 2). In the fully adjusted model with age, BMI, smoking status, 
education and race/ethnicity, each interquartile range increase (comparing the 25th percentile 
with the 75th
 In a model that included both oestradiol and FSH, the associations remained unchanged 
(data not shown). We also evaluated potential effect modification by baseline obesity status but 
the associations were similar, independently of baseline obesity status (data not shown).  
 percentile) in the oestradiol intercept (75.2 pmol/L) was borderline significantly 
associated with lower risk of incident diabetes (hazard ratio 0.53, 95% CI 0.27–1.06; P = 0.07). 
For FSH, a greater rate of increase > 2 years before the final menstrual period (early transition) 
was significantly associated with lower risk of incident diabetes, but the baseline (pre-
menopausal) FSH level or the rate of change in FSH between 2 years before and 2 years after the 
final menstrual period (late transition) were not associated with incident diabetes. The fully 
adjusted hazard ratio of diabetes for an interquartile range increase (5.9 IU/L/year) in early 
transition FSH rate of change was 0.31 (95% CI 0.10–0.94; P = 0.04). We also compared the 
goodness-of-fits between the model with only covariates included in Model 3 (AIC=1869.73) 
and the model with covariates and each hormone (AIC=1693.77 for oestradiol; AIC=1683.01 for 
FSH). Both oestradiol and FSH significantly improved the model goodness-of-fit (P<0.0001).   
 
Discussion 
This is the first study to prospectively examine the associations between levels of and 
change in oestradiol and FSH over the menopausal transition and incident diabetes in a cohort of 
women. We observed that independent of age, women with higher endogenous oestradiol levels 
at baseline (i.e. 7 years before the final menstrual period) in the pre-menopause and early peri-
menopause had a lower risk of developing diabetes in mid-life as they transitioned through the 
menopause. The rate of change in oestradiol during the menopausal transition did not appear to 
be associated with diabetes risk. By contrast, a steeper increase in FSH from ~7 to 2 years before 
the final menstrual period (i.e. during the early menopausal transition) was associated with a 
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lower risk of developing diabetes. Neither baseline FSH levels nor change in FSH in the later 
menopausal transition were associated with incident diabetes. These findings suggest that pre-
menopausal levels of oestradiol rather than the rate of change during the menopausal transition, 
and the rate of FSH change in the early stage of the menopausal transition rather than pre-
menopausal levels or the rate of change in late perimenopause, are associated with diabetes risk 
during mid-life. 
The observed association between pre-menopausal oestradiol levels and incident diabetes 
may be partially explained by different patterns of oestradiol by the presence of obesity. 
Randolph et al. [14] reported that obese women compared with non-obese women had lower pre-
menopausal oestradiol levels but higher post-menopausal oestradiol levels in SWAN (Fig. 1). 
Obesity has a direct inhibitory effect on the ovarian oestradiol production in pre-menopausal 
women [22,23]. Adipose tissue is an important source of oestrogens by aromatization of 
androgens after menopause [24,25]. Such body fat distribution changes as well as increased 
proinflammatory cytokines during the menopausal transition have been associated with glucose 
homeostasis [26,27]. Slower oestradiol change in obese women during the menopausal transition 
may in part be attributable to this production of oestrogens in adipose tissue [14] and may offset 
the oestradiol effect on diabetes risk. This may be why we found a significant association of 
diabetes risk with pre-menopausal oestradiol levels but not the rate of oestradiol change during 
the menopausal transition. Despite a post-menopausal shift of oestrogen production from the 
ovary to adipose tissue, as endogenous oestradiol levels substantially decline through the 
menopausal transition, obesity-related insulin resistance may play a larger role in diabetes risk.  
Our finding of no association between the rates of change in oestradiol during early and 
late transition and diabetes risk does not necessarily mean that oestradiol has no impact on 
diabetes risk in post-menopausal women because previous studies in post-menopausal women 
observed that higher oestradiol levels were associated with increased risk of diabetes even after 
adjusting for an indicator of adiposity (e.g. BMI) [10,11]. In a nested case–control study of 359 
incident diabetes cases and 359 age-, race-, duration of follow-up- and fasting status-matched 
controls among post-menopausal women in the Women’s Health Study, Ding et al. [10] 
observed adjusted relative risks of diabetes comparing the highest with the lowest quintile of 
12.6 (95% CI 2.8–56.3) for total oestradiol and 13.1 (95% CI 4.2–40.8) for free oestradiol [10]. 
In a prospective cohort study with 1612 diabetes-free post-menopausal women in the Multi-
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Ethnic Study of Atherosclerosis, the highest quartile of oestradiol had an adjusted hazard ratio of 
1.92 (95% CI 1.10–3.35) compared with the lowest quartile [11]. A relatively small study with 
233 women aged 55–85 years in the Rancho Bernardo Study reported that women in the top 
quartile of total oestradiol and bioavailable oestradiol compared with the bottom three quartiles 
had odds ratios of incident diabetes of 1.3 (95% CI 0.4–4.6) and 1.9 (95% CI 0.7–5.3), 
respectively [12].  
Obesity-related patterns of relative change in FSH during the menopausal transition may 
also explain the observed association between FSH change and incident diabetes. Pre-
menopausal FSH levels do not seem to differ between obese and non-obese women but obese 
women have a markedly slower rate of FSH increase during the late transition and have lower 
FSH levels after menopause (Fig. 1) [14,23]. In the present study, risk of developing diabetes 
was associated with the rate of FSH change during the early transition, but not during the late 
transition. This finding suggests that, although the obesity–FSH trajectory association indicates 
the period from late transition to early post-menopause is a critical window of obesity-related 
difference in FSH levels, diabetes risk may begin earlier. Underlying biological mechanisms are 
unclear as roles of FSH in glucose metabolism and diabetes risk are poorly understood. 
Epidemiological evidence is also scant. A recent study conducted in East China in 1610 post-
menopausal women not using hormone therapy (aged 55–89 years) reported that FSH was 
significantly inversely associated with fasting glucose and HbA1c 28 [ ]. Women in the lowest 
quartile of FSH compared with the highest quartile had a threefold greater odds of diabetes (95% 
CI 1.10–8.31) in the fully adjusted model, including measures of adiposity and insulin resistance 
and oestradiol [28]. It is difficult to compare our findings directly with those of the previous 
studies on FSH and oestradiol and diabetes because none of these studies examined pre-
menopausal oestradiol and FSH levels or changes in oestradiol and FSH during the menopausal 
transition. Further longitudinal studies need to be conducted to replicate our findings.  
Although cigarette smoking may also play a role in diabetes risk, the observed 
associations appear to be independent of cigarette smoking. Cigarette smoking can influence 
ovarian function and reduce endogenous oestrogen production by accelerating regression of 
follicles in the ovary and blocking aromatase [29];  however, Randolph et al. [14] found no 
difference by smoking status in trajectories of oestradiol and FSH across the menopausal 
transition in SWAN. The association of pre-menopausal oestradiol level or change in FSH during 
Au
th
or
 M
an
us
cr
ip
t
This article is protected by copyright. All rights reserved 
the early menopausal transition with incident diabetes remained unchanged after adjustment for 
cigarette smoking. In the present analysis, cigarette smoking was significantly associated with 
incident diabetes, as suggested in a recent meta-analysis [30]. 
The present study did not observe significant effect modification by baseline obesity. 
Given our research question, we were unable to test if weight gain during the menopausal 
transition (i.e. time-varying obesity status) modified the association between changes in 
oestradiol or FSH and incident diabetes risk; therefore, the present finding of no effect 
modification by baseline obesity does not necessarily imply that weight gain during the 
menopausal transition does not confer susceptibility to sex-hormone-related diabetes risk. A 
more sophisticated model, such as a marginal structural model, may be useful to better 
understand the role of weight gain in the association between sex hormones and diabetes.  
The present study has numerous strengths. Annualized measures of sex steroid hormones 
for up to 15 years allow us to separate out the effect of baseline levels vs rate of change in 
hormone levels during the menopausal transition. Repeated measures of sex hormones account 
for within-individual variations and thus minimize a potential exposure measurement error 
attributable to a single cross-sectional measurement. The study design enabled us to identify an 
important window of susceptibility to diabetes risk related to endogenous hormone levels that 
may inform appropriate timing for clinical screening and intervention. The ethnically diverse 
population in the SWAN cohort increases the generalizability of our findings. This paper also 
has some limitations. Measurement of diabetes onset at visits 9 and 10 was based only on 
medication use and self-report. Thus, some cases ascertained at visit 12 may have had an earlier 
onset; however, this delay in ascertainment would only have affected our results if cases were 
misclassified as being in late peri-menopause when they were in fact in early peri-menopause. 
As <15% of the participants were still pre- or early peri-menopausal at visit 9, such 
misclassification would be minimal. In stage 1 where the hormone trajectory models were 
estimated, we did not completely restrict hormone data only before the diabetes onset. This may 
have biased our findings in stage 2 if diabetes influenced the rates of change in sex hormones 
across the menopausal transition. The impact of this would be minimal, however, because only 
1.7% of the hormone data were gathered after the diabetes onset. We also cannot exclude the 
possibility of unmeasured or residual confounding.  
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In conclusion, in the present study we found that lower pre-menopausal oestradiol levels 
and a slower rate of FSH increase during the early transition were associated with a higher risk 
of developing diabetes as women transition through the menopause, independently of age and 
obesity. Given that obesity and excess fat play an important role in not only diabetes risk itself 
but the changes in oestradiol and FSH over the menopausal transition, these findings provide 
support for the relevance of an important strategy for preventive intervention: weight control in 
earlier mid-life is important to prevent future diabetes development. These results suggest the 
importance of monitoring for diabetes during the menopausal transition as well as the importance 
of adopting healthy diets and increasing exercise during this life stage.  
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FIGURE 1 Schematic trajectories of oestradiol and follicle stimulating hormone (FSH) around 
the final menstrual period (FMP) by obesity status. 
 
 Table 1 Baseline characteristics of 1407 women in the Study of Women’s Health Across the 
Nation with an observed natural final menstrual period and without diabetes at baseline  
 All Incident diabetes 
  No Yes 
Number of women 1407 1275 132 
Mean ± SD age, years  46.4 ± 2.7 46.4 ± 2.7 46.8 ± 2.8 
Mean ± SD age at FMP, years  51.8 ± 2.7 51.8 ± 2.8 51.8 ± 2.5 
Menopausal status, %  *   
   Pre-menopause 57.3 58.1 49.2 
   Early peri-menopause 42.7 41.9 50.8 
Race/ethnicity‡  , %   
   White 43.6 45.0 29.6 
   Black 28.8 26.6 50.0 
   Hispanic 5.9 5.5 9.9 
   Chinese 10.3 11.0 3.8 
   Japanese 11.4 11.9 6.8 
Education‡  , %   
   < High school 6.7 5.8 15.4 
   High school 16.6 15.9 23.1 
   Some college 31.3 31.1 33.1 
   4-year college 21.9 22.6 15.4 
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   >4-year college 23.5 24.6 13.1 
Site‡  , %   
   Detroit, MI 16.4 14.9 30.3 
   Boston, MA 15.2 15.2 15.2 
   Chicago, IL 14.9 14.6 17.4 
   Oakland, CA 16.2 17.2 6.8 
   Los Angeles, CA 16.8 17.5 9.9 
   Newark, NJ 8.8 8.6 10.6 
   Pittsburgh, PA 11.8 12.0 9.9 
Smoking status†  , %   
   Never 59.8 60.5 53.0 
   Former 23.7 24.1 20.5 
   Current 16.4 15.4 26.5 
Obesity, % 28.5 25.3 59.1 
Sex hormone, median (Q1, Q3)    
   Oestradiol*, pmol/L  211.4 (121.1, 322.2) 213.6 (124.4, 324.4) 160.4 (113.8, 274.9) 
   FSH, IU/L  16.5 (11.4, 27.6) 16.6 (11.3, 27.6) 16.2 (11.6, 27.1) 
*P<0.05, †P<0.01, ‡P<0.0001 based on chi-squared test for categorical variables and Wilcoxon rank-sum test for continuous 
variables for comparing those with and without incident diabetes.
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Table 2 Regression coefficients from Cox models and hazard ratios for incident diabetes for an interquartile range increase*
 
 in 
variables of the longitudinal change in hormone levels among 1407 women, Study of Women’s Health Across the Nation 
Model 1 Model 2 Model 3 
 β (SE) HR (95% CI) β (SE) HR (95% CI) β (SE) HR (95% CI) 
Oestradiol       
   Intercept (pre-menopausal) -0.0316 (0.0144) 0.52 (0.29, 0.93) -0.0218 (0.0160) ‡ 0.64 (0.34, 1.22) -0.0309 (0.0171) 0.53 (0.27, 1.06)† 
   Slope for early transition 0.0377 (0.0659) 1.07 (0.84, 1.37) 0.0178 (0.0699) 1.03 (0.80, 1.34) 0.0539 (0.0764) 1.11 (0.83, 1.47) 
   Slope for late transition -0.0321 (0.0184) 0.61 (0.35, 1.06) -0.0196 (0.0213) 0.74 (0.39, 1.41) -0.0311 (0.0223) 0.62 (0.32, 1.21) 
FSH       
   Intercept (pre-menopausal) 0.0054 (0.0139) 1.20 (0.48, 3.00) 0.0117 (0.0141) 1.48 (0.58, 3.77) 0.0121 (0.0141) 1.51 (0.59, 3.81) 
   Slope for early transition -0.2360 (0.0910) 0.25 (0.09, 0.71) -0.1787 (0.0904) ¶ 0.35 (0.12, 0.99) -0.1953 (0.0947) ‡ 0.31 (0.10, 0.94)‡ 
   Slope for late transition 0.0261 (0.0276) 1.33 (0.74, 2.39) 0.0134 (0.0265) 1.16 (0.66, 2.03) 0.0257 (0.0288) 1.32 (0.72, 2.44) 
FSH, follicle-stimulating hormone; HR, hazard ratio. 
Model 1: adjusted for baseline age; Model 2: Model 1 + baseline BMI; Model 3: Model 2 + race/ethnicity, education and smoking status.  
*Interquartile ranges for the oestradiol model: 75.2 pmol/L for the intercept; 7.0 pmol/L/year for the early transition slope; 56.5 pmol/L/year for the late transition slope. IQRs for 
the FSH model: 33.7 IU/L for the intercept; 5.9 IU/L/year for the early transition slope; 10.8 IU/L/year for the late transition slope.  
†P<0.1, ‡P<0.05, ¶P<0.01.  
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